We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Following a safety review, the FDA has added additional warnings to the labels of SGLT2 inhibitors for diabetes because they can cause the body to produce too much acid in the blood or lead to serious urinary tract infections. Read More
The FDA is eliminating the risk evaluation and mitigation strategy for rosiglitazone-containing diabetes drugs, deciding enough is understood about its side effects. Read More
Heritage Pharmaceuticals has been hit with a warning letter for what the FDA calls “serious violations” of postmarket reporting requirements. Read More
Type 2 diabetes drugs have elevated reporting rates for pancreatitis, hypoglycemia and diabetic ketoacidosis, which adds to suspicions of class-wide side effect issues, especially for DPP-4 drugs, a new analysis from Advera Health Analytics said. Read More
Following a safety review, the FDA has added additional warnings to the labels of SGLT2 inhibitors for diabetes because they can cause the body to produce too much acid in the blood or lead to serious urinary tract infections. Read More
Generic manufacturer Heritage Pharmaceuticals has been hit with a warning letter for what the FDA calls “serious violations” of postmarket reporting requirements. Read More